Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

In the preceding three months, 12 analysts have released ratings for Vertex (NASDAQ:VERX), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a ...

Vertex Pharmaceuticals Incorporated (VRTX ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

On the other hand, the Dow registered a loss of 0.06%, and the technology-centric Nasdaq increased by 1.24%. The investment community will be closely monitoring the performance of Vertex ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

The increasing adoption of e-invoicing globally and the ongoing enterprise resource planning (ERP) migration super cycle present multi-year growth opportunities for Vertex. As companies shift to ...

Vertex's CEO, Reshma Kewalramani ... the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Vertex Pharmaceuticals (VRTX ... Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 1.24%. The drugmaker's shares have seen a decrease of ...

Vertex is funding the three-year research collaboration ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...